Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 7Genitourinary 4Other hematologic neoplasm 3Lymphoid 2Breast 2Sarcoma 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 2Gastrointestinal Neoplasms 1Fatigue 1Cognitive Dysfunction 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Methylphenidate × Breast × Clear all
NCT02970500 2023-03-23

CogMet

CHU de Quebec-Universite Laval

Phase 2 Terminated
20 enrolled
Breast

Breast Neoplasms, Cognitive Dysfunction

NCT00516269 2018-01-03

Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients

M.D. Anderson Cancer Center

Phase 3 Terminated
42 enrolled 8 charts
BreastGastrointestinal

Breast Neoplasms, Fatigue, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡